Forex Magnum


5 Stocks Quietly Riding the Trends


These companies are growing steadily in sectors where we’ll see the next megatrends appear, writes Michael Murphy of New World Investor.

Paramount Gold & Silver (PZG) said the first analysis of the waste heaps at their Sleeper Mine showed 0.27 grams per tonne of gold, with a likely recovery rate of 70%. So, let’s do the math:

Or, they hire a recovery company, pay the startup and operating expenses themselves, and keep something over $500 million or $3.50-plus a share.

Buy PZG under $4 for my $15 target when the company is acquired, possibly in 2011. There is a lot of good news coming, including the announcement that the Sleeper waste dumps contain $70 million worth of gold to fund the company.

Antares Pharma (AIS) is only days away from FDA approval of Anturol, and not much more than that from BioSante’s (BPAX) release of the Phase III LibiGel data.

Female sexual dysfunction, or Hypoactive Sexual Desire Disorder (HSDD), affects millions of women in the US, especially those past menopause. It is more common than erectile dysfunction, which is a $2 billion per year prescription business in the US. There currently are no FDA approved drug therapies for the treatment of HSDD in women.

Projections for the US market alone range from $2 billion to $5 billion in sales. Not only does Antares get a royalty on that, but they own the rest-of-world rights. AIS remains a top buy trading idea up to $3 for a $5 target by the end of 2011.

Dendreon (DNDN) said that in 2013 they’ll do a Provenge trial in earlier-stage prostate cancer, setting the stage for an important label expansion. Most of the new “competitors” to Provenge actually aim at later-stage patients, and success in earlier-stage patients would substantially broaden Provenge’s market.

In this trial, the placebo will be a true placebo, not the frozen Provenge that was used in the approval trials. The company expects a much higher overall survival advantage due to this change. The widely-quoted 4.1-month survival advantage was for Provenge competing against frozen Provenge, a little fact the Dendreon bears never mention.

DNDN is a top buy under $28 with a $50 target as they roll out Provenge, bring on more manufacturing capacity, and file for approval in Europe.

Sprint (S) and Clearwire are engaged in a game of chicken over whether Clearwire will make its $237 million debt payment due on December 1. They have a 30-day grace period, and I would not be surprised to see this whole issue resolved, with another partner announced, by the end of the year.

S is a top buy trading idea under $4 for my $8 target in 2012—which I expect to raise.

3D Systems (DDD) is acquiring Z Corporation, the leading multicolor inkjet 3D printer, for $137 million in cash. Z Corporation did the adjustable wrench manufacturing that I showed in the original DDD recommendation.

DDD also gets Vidar Systems in the deal. Vidar is a leader in medical imaging, and will offer 3D medical models, surgical guides, hearing aids, dental applications, and implantable devices. The acquisitions should close just after the end of the year.

DDD is a top buy under $17 for a $27 target price in 2012.

Subscribe to New World Investor here…

Related Reading:


Sei un Analista Tecnico Indipendente Professionista del mercato FOREX? Registrati anche tu nella comunità ed elabora insieme a noi strategie automatiche di successo! Dettagli


Sai programmare in MQL o usare il MetaTrading? Registrati e contribuisci alla programmazione di trading system, script e indicatori per MetaTrader. Dettagli


Ti piace il Trading? Vieni in Trading Room a Cosenza, guarda le analisi tecniche real time dei nostri indicatori e decidi quando entrare nel mercato. Corsi base ed avanzati. Dettagli

Non esistono ancora Commenti per questa news.

Archivio News


1 2 3 4 5 > >>

This Distributor Is a Bargain

10 Comeback Stories to Watch in 2012

Bouncing Back, Five Cents at a Time

8 Stocks for a Flourishing Income Portfolio

Quantitative Easing and Its Impact on Gold

Option Outlook 2012

Market Outlook 2012

Five Step Trading

3 Stocks Show: ‘It’s Earnings, Stupid’

3 “Golden Rules” of Forex Trading

2 Rock-Solid Short-Term Bond Funds

This is Not a Test…It’s a Buy

4 Bright Spots in a Bear Market

Top Resource Stocks for 2012 on Sale

This Growth Stock Remains in Style

This Stock’s P/E Proves its Potential

A New Day for the Airline Industry

6 Metals Plays Primed for Strong Gains

3 Little Names That Can in 2012

This Classy Retailer Is Above the Fray

An Easy and Effective Way to Buy MLPs

Want to Diversify? Start with These 5

3 Names Right out of Santa’s Gift Bag

5 Income Stocks That Defy Volatility

5 Stocks Quietly Riding the Trends


1 2 3 4 5 > >>